Advertisement

Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications

Published:October 11, 2017DOI:https://doi.org/10.1016/j.ajog.2017.10.006

      Background

      Women with refractory urgency urinary incontinence (ie, unresponsive to behavioral and pharmacological interventions) are treated with onabotulinumtoxinA or sacral neuromodulation.

      Objective

      The objective of the study was to compare treatment efficacy and adverse events in women <65 and ≥65 years old treated with onabotulinumtoxinA or sacral neuromodulation.

      Study Design

      This study was a planned secondary analysis of a multicenter, randomized trial that enrolled community-dwelling women with refractory urgency urinary incontinence to onabotulinumtoxinA or sacral neuromodulation treatments. The primary outcome was a change in mean daily urgency urinary incontinence episodes on a bladder diary over 6 months. Secondary outcomes included ≥75% urgency urinary incontinence episode reduction, change in symptom severity/quality of life, treatment satisfaction, and treatment-related adverse events.

      Results

      Both age groups experienced improvement in mean urgency urinary incontinence episodes per day following each treatment. There was no evidence that mean daily urgency urinary incontinence episode reduction differed between age groups for onabotulinumtoxinA (adjusted coefficient, –0.127, 95% confidence interval, –1.233 to 0.979; P = .821) or sacral neuromodulation (adjusted coefficient, –0.698, 95% confidence interval, –1.832 to 0.437; P = .227). Among those treated with onabotulinumtoxinA, women <65 years had 3.3-fold greater odds of ≥75% resolution than women ≥65 years (95% confidence interval, 1.56 –7.02). Women <65 years had a greater reduction in Overactive Bladder Questionnaire Short Form symptom bother scores compared with women ≥65 years by 7.49 points (95% confidence interval, –3.23 to –11.74), regardless of treatment group. There was no difference between quality of life improvement by age. Women ≥65 years had more urinary tract infections following onabotulinumtoxinA and sacral neuromodulation (odds ratio, 1.9, 95% confidence interval, 1.2–3.3). There was no evidence of age differences in sacral neuromodulation revision/removal or catheterization following onabotulinumtoxinA treatment.

      Conclusion

      Younger women experienced greater absolute continence, symptom improvement, and fewer urinary tract infections; both older and younger women had beneficial urgency urinary incontinence episode reduction, similar rates of other treatment adverse events, and improved quality of life.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Willis-Gray M.G.
        • Dieter A.A.
        • Geller E.J.
        Evaluation and management of overactive bladder: strategies for optimizing care.
        Res Rep Urol. 2016; 8: 113-122
        • Stewart W.F.
        • Van Rooyen J.B.
        • Cundiff G.W.
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
        • Kraus S.R.
        • Bavendam T.
        • Brake T.
        • Griebling T.L.
        Vulnerable elderly patients and overactive bladder syndrome.
        Drugs Aging. 2010; 27: 697-713
        • Seigel S.
        • Noblett K.
        • Mangel J.
        • et al.
        Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
        Neurourol Urodyn. 2015; 34: 224-230
        • Visco A.G.
        • Brubaker L.
        • Richter H.E.
        • et al.
        Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence.
        N Engl J Med. 2012; 367: 1803-1813
        • McMurdo M.E.T.
        • Roberts H.
        • Parker S.
        • et al.
        Improving recruitment of older people to research through good practice.
        Age Ageing. 2011; 40: 659-665
        • Amundsen C.
        • Richter H.E.
        • Menefee S.A.
        • et al.
        OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women. A randomized clinical trial.
        JAMA. 2016; 316: 1366-1374
        • Groll D.L.
        • To T.
        • Bombardier C.
        • Sexton C.C.
        The development of a comorbidity index with physical function as the outcome.
        J Clin Epidemiol. 2005; 58: 595-602
        • Coyne K.S.
        • Thompson C.L.
        • Lai J.-S.
        • et al.
        An Overactive Bladder symptoms and Health-Related Quality of Life Short-Form: validation of the OAB-q SF.
        Neurourol Urodyn. 2015; 34: 255-263
        • Sandvik H.
        • Seim A.
        • Vanvik A.
        • Hunskaar S.
        A severity index for epidemiological surveys of female urinary incontinence comparison with 48-hour pad-weighing tests.
        Neurourol Urodyn. 2000; 19: 137-145
        • Uebersax J.S.
        • Wyman J.F.
        • Shumaker S.A.
        • McClish D.K.
        • Fantl J.A.
        • Continence Program for Women Research Group
        Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory.
        Neurourol Urodyn. 1995; 14: 131-139
        • Feeny D.
        • Furlong W.
        • Torrance G.W.
        • et al.
        Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system.
        Med Care. 2002; 40: 113-128
        • Peel C.
        • Baker P.S.
        • Roth D.L.
        • Brown C.J.
        • Brodner E.V.
        • Allman R.M.
        Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment.
        Phys Ther. 2005; 85: 1008-1019
        • Yalcin I.
        • Bump R.C.
        Validation of two global impression questionnaires for incontinence.
        Am J Obstet Gynecol. 2003; 189: 98-101
        • Margolis M.K.
        • Fox K.M.
        • Cerulli A.
        • Ariely R.
        • Kahler K.H.
        • Coyne K.S.
        Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
        Neurourol Urodyn. 2009; 28: 416-421
        • DuBeau C.E.
        • Kuchel G.A.
        • Johnson II, T.
        • Palmer M.H.
        • Wagg A.
        Incontinence in the frail elderly: report from the Fourth International Consultation on Incontinence.
        Neurourol Urodyn. 2010; 29: 165-178
        • DuBeau C.E.
        The aging lower urinary tract.
        J Urol. 2006; 175: S11-S15
        • Norman G.R.
        • Sloan J.A.
        • Wyrwich K.W.
        Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.
        Med Care. 2003; 41: 582-592
        • Coyne K.S.
        • Matza L.S.
        • Thompson C.L.
        • Kopp Z.S.
        • Khullar V.
        Determining the importance of change in the overactive bladder questionnaire.
        J Urol. 2006; 176: 627-632
        • Cohen B.L.
        • Caruso D.J.
        • Kanagarajah P.
        • Gousse A.E.
        Predictors of response to intradetrusor botulinum toxin-A Injections in patients with idiopathic overactive bladder.
        Adv Urol. 2009; : 328364
        • Amundsen C.L.
        • Romero A.A.
        • Jamison M.G.
        • Webster G.D.
        Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?.
        Urology. 2005; 66: 746-750
        • De Riggo J.
        • Benco M.
        • Kolarovszki B.
        • et al.
        Urinary incontinence in degenerative spinal disease.
        Acta Chir Traumatol Cech. 2011; 78: 67-70
        • Eisenstein S.M.
        • Engelbrecht D.J.
        • el Masry W.S.
        Low back pain and urinary incontinence. A hypothetical relationship.
        Spine. 1994; 19: 1148-1152
        • Scheepens W.A.
        • Jongen M.M.G.J.
        • Nieman F.H.M.
        • de Bie R.A.
        • Weil E.H.
        • van Kerrebroeck P.E.
        Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction.
        Urology. 2002; 60: 598-602
        • Foxman B.
        • Barlow R.
        • D’Arcy H.
        • Gillespie B.
        • Sobel J.D.
        Urinary tract infection: self-reported incidence and associated costs.
        Ann Epidemiol. 2000; 10: 509-515
        • Eriksson I.
        • Gustafson Y.
        • Fagerström L.
        • Olofsson B.
        Prevalence and factors associated with urinary tract infections (UTIs) in very old women.
        Arch Gerontol and Geriatrics. 2010; 50: 132-135
        • Miotla P.
        • Cartwright R.
        • Skorupska K.
        • et al.
        Urinary retention in female OAB after intravesical Botox injection: who is really at risk?.
        Int Urogynecol J. 2017; 28: 845-850